Author

B Godwin

Institution: Janssen Research & Development (United States)

Observed institutions: Janssen Scientific Affairs (United States), Janssen Research & Development (United States)

OpenAlex ID: A5000855284

P436 Efficacy and safety of intravenous ustekinumab re-induction therapy in Crohn’s disease patients with secondary loss of response to ustekinumab maintenance therapy: Week 16 results from the POWER trial

2023 · S W Schreiber, S Lee, et al. · Journal of Crohn s and Colitis · 12

P1123 Baseline characteristics and nutrition in patients with moderately to severely active Inflammatory Bowel Disease: Results from the phase 3 UNITI Jr and UNIFI Jr trials

2025 · E De Greef, É Kosaras, et al. · Journal of Crohn s and Colitis · 1

P553 Active tuberculosis and opportunistic infections: Pooled safety analysis of ustekinumab through up to 5 years across all approved indications

2023 · S Ghosh, M Long, et al. · Journal of Crohn s and Colitis · 1

P115 Ustekinumab in DEVELOP: A safety analysis from an Inflammatory Bowel Disease multicenter, prospective, long-term registry of paediatric patients

2024 · S Koletzko, G Veereman, et al. · Journal of Crohn s and Colitis

Works count: 4

Citation count: 14

H-index: 1

I10-index: 1